Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado trimmed its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,333 shares of the medical equipment provider’s stock after selling 1,925 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Intuitive Surgical were worth $20,087,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of ISRG. Vanguard Group Inc. increased its holdings in Intuitive Surgical by 1.6% in the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after acquiring an additional 272,741 shares during the period. Capital World Investors boosted its position in shares of Intuitive Surgical by 1.0% during the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock worth $2,907,079,000 after buying an additional 73,634 shares during the period. Edgewood Management LLC boosted its position in shares of Intuitive Surgical by 7.9% during the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock worth $1,731,016,000 after buying an additional 374,667 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Intuitive Surgical by 2.0% during the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after buying an additional 88,977 shares during the period. 83.64% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Mark J. Rubash sold 1,709 shares of Intuitive Surgical stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $380.00, for a total value of $649,420.00. Following the sale, the director now owns 16,051 shares of the company’s stock, valued at approximately $6,099,380. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The disclosure for this sale can be found here. Insiders have sold a total of 12,982 shares of company stock worth $5,451,547 over the last 90 days. Insiders own 0.90% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price target on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. Morgan Stanley increased their price objective on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Evercore ISI decreased their target price on Intuitive Surgical from $425.00 to $410.00 and set an “in-line” rating for the company in a research report on Friday, July 19th. Finally, Truist Financial upped their target price on Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Six equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $438.74.

Intuitive Surgical Price Performance

Shares of NASDAQ:ISRG traded up $1.15 during midday trading on Monday, reaching $442.45. The company’s stock had a trading volume of 509,716 shares, compared to its average volume of 1,554,532. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $468.78. The company has a market capitalization of $157.22 billion, a P/E ratio of 79.66, a P/E/G ratio of 4.86 and a beta of 1.39. The business’s fifty day simple moving average is $427.82 and its 200-day simple moving average is $398.79.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period last year, the company posted $1.18 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. On average, analysts forecast that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.